Current views on interferon therapy for HIV

References

• Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957;147:258–267. doi:10.1098/rspb.1957.0048.
   PubMed Web of Science ®Google Scholar
• Isaacs A, Lindenmann J, Valentine RC. Virus interference. II. Some properties of interferon. Proc R Soc Lond B Biol Sci. 1957;147:268–273. doi:10.1098/rspb.1957.0049.
   PubMed Web of Science ®Google Scholar
• Lane HC. The role of alpha-interferon in patients with human immunodeficiency virus infection. Semin Oncol. 1991;18(Suppl 7):46–52.
   PubMed Web of Science ®Google Scholar
• Asmuth DM, Utay NS, Pollard RB. Peginterferon α-2a for the treatment of HIV infection. Expert Opin Investig Drugs. 2016;25:249–257. doi:10.1517/13543784.2016.1132699.
   PubMed Web of Science ®Google Scholar
• Sandler NG, Bosinger SE, Estes JD, et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature. 2014;511:601–605. doi:10.1038/nature13554.
   PubMed Web of Science ®Google Scholar
• Tomescu C, Mavilio D, Montaner LJ. Lysis of HIV-1- infected autologous CD4+ primary T cells by interferon alpha-activated NK cells requires NKp46 and NKG2D. AIDS. 2015;29:1767–1773. doi:10.1097/QAD.0000000000000777.
   PubMed Web of Science ®Google Scholar
• Biron CA. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin Immunol. 1998;10:383–390. doi:10.1006/smim.1998.0138.
   PubMed Web of Science ®Google Scholar
• Foster GR. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs. 2010;70:147–165. doi:10.2165/11531990-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2010;138:116–122. doi:10.1053/j.gastro.2009.10.005.
   PubMed Web of Science ®Google Scholar
• Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010;138:108–115. doi:10.1053/j.gastro.2009.08.071.
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–593. doi:10.1056/NEJMoa0808010.
   PubMed Web of Science ®Google Scholar
• Lane HC, Kovacs JA, Feinberg J, et al. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi’s sarcoma. Lancet. 1988;2:1218–1222.
   PubMed Web of Science ®Google Scholar
• Rivero J, Limonta M, Aguilera A, et al. Use of recombinant interferon-alpha in human immunodeficiency virus (HIV)-infected individuals. Biotherapy. 1994;8:23–31.
   PubMedGoogle Scholar
• Rivero J, Fraga M, Cancio I, et al. Long-term treatment with recombinant interferon alpha-2b prolongs survival of asymptomatic HIV-infected individuals. Biotherapy. 1997;10:107–113. doi:10.1007/BF02678537.
   PubMedGoogle Scholar
• Huang SS, Skolasky RL, Dal Pan GJ, et al. Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-Interferon: an observational study. J Neurovirol. 1998;4:324–332. doi:10.3109/13550289809114533.
   PubMed Web of Science ®Google Scholar
• Suthar AB, Granich RM, Kato M, et al. Programmatic implications of acute and early HIV infection. J Infect Dis. 2015;212:1351–1360. doi:10.1093/infdis/jiv430.
   PubMed Web of Science ®Google Scholar
• Altfeld M, Gale M Jr. Innate immunity against HIV-1 infection. Nat Immunol. 2015;16:554–562. doi:10.1038/ni.3157.
   PubMed Web of Science ®Google Scholar
• Hardy GA, Sieg S, Rodriguez B, et al. Interferon-α is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers. PLoS ONE. 2013;8:e56527. doi:10.1371/journal.pone.0056527.
   Google Scholar
• Doyle T, Goujon C, Malim MH. HIV-1 and interferons: who’s interfering with whom? Nat Rev Microbiol. 2015;13:403–413. doi:10.1038/nrmicro3449.
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced immunodeficiency virus infection. N Engl J Med. 1998;338:853–860. doi:10.1056/NEJM199803263381301.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet. 1998;352:1725–1730.
   PubMed Web of Science ®Google Scholar
• Lisziewicz J, Rosenberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med. 1999;340:1683–1684. doi:10.1056/NEJM199905133401909.
   PubMed Web of Science ®Google Scholar
• Lori F, Lisziewicz J. Structured treatment interruptions for the management of HIV infection. JAMA. 2001;286:2981–2987.
   PubMed Web of Science ®Google Scholar
• Hogg RS, Havlir D, Miller V, et al. To stop or not to stop: that is the question, but what is the answer? AIDS. 2002;16:787–789.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Ripamonti D, Gregis G, et al. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective study. AIDS. 2004;18:439–446.
   PubMed Web of Science ®Google Scholar
• Cardiello PG, Hassink E, Ananworanich J, et al. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis. 2005;40:594–600. doi:10.1086/427695.
   PubMed Web of Science ®Google Scholar
• Ananworanich J, Siangphoe U, Hill A, et al. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4- guided therapy achieved similar virologic suppression compared with patients on continuous HAART. J Acquir Immune Defic Syndr. 2005;39:523–529.
   PubMed Web of Science ®Google Scholar
• Fagard C, Oxenius A, Gunthard H, et al. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med. 2003;163:1220–1226. doi:10.1001/archinte.163.10.1220.
   PubMedGoogle Scholar
• Dianzani F, Rozera G, Abbate I, et al. Interferon may prevent HIV viral rebound after HAART interruption in HIV patients. J Interferon Cytokine Res. 2008;28:1–3. doi:10.1089/jir.2007.0076.
   PubMed Web of Science ®Google Scholar
• Boué F, Reynes J, Rouzioux C, et al. Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial. Aids. 2011;25:115–118. doi:10.1097/QAD.0b013e328340a1e7.
   PubMed Web of Science ®Google Scholar
• Goujard C, Emilie D, Roussillon C, et al. Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM trial. AIDS. 2012;26:1895–1905.
   PubMed Web of Science ®Google Scholar
• El-Sadr WM, Lundgren J, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–2296. doi:10.1056/NEJMoa062360.
   PubMed Web of Science ®Google Scholar
• Montes ML, Schapiro J, Perez-Valero I, et al. Long-term control of HIV replication with dolutegravir and pegylated interferon alpha-2a in an HIV-infected patient with sixtuple-class resistance. AIDS. 2014;28:932–934. doi:10.1097/QAD.0000000000000208.
   PubMed Web of Science ®Google Scholar
• Doyle T, Dunn DT, Ceccherini-Silberstein F, et al. Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades. J Antimicrob Chemother. 2015;70:3080–3086. doi:10.1093/jac/dkv243.
   PubMed Web of Science ®Google Scholar
• Barton K, Winckelmann A, Palmer S. HIV-1 reservoirs during suppressive therapy. Trends Microbiol. 2016;24:345–355. doi:10.1016/j.tim.2016.01.006. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Chun TW, Finzi D, Margolick J, et al. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med. 1995;1:1284–1290.
   PubMed Web of Science ®Google Scholar
• Rezaei SD. Cameron PU. Human Immunodeficiency Virus (HIV)-1 integration sites in viral latency. Curr HIV/AIDS Rep. 2015;12:88–96. doi:10.1007/s11904-014-0241-9.
   PubMed Web of Science ®Google Scholar
• Edagwa BJ, Zhou T, McMillan JM, et al. Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies. Curr Med Chem. 2014;21:4186–4198.
   PubMed Web of Science ®Google Scholar
• Calcagno A, Di Perri G, Bonora S. Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system. Clin Pharmacokinet. 2014;53:891–906. doi:10.1007/s40262-014-0171-0.
   PubMed Web of Science ®Google Scholar
• Fletcher CV, Staskus K, Wietgrefe SW, et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci USA. 2014;111:2307–2312. doi:10.1073/pnas.1318249111.
   PubMed Web of Science ®Google Scholar
• Johns TG, Kerry JA, Veitch BA, et al. Pharmacokinetics, tissue distribution, and cell localization of [35S] methionine-labeled recombinant human and murine alpha interferons in mice. Cancer Res. 1990;50:4718–4723.
   PubMed Web of Science ®Google Scholar
• Alammar L, Gama L, Clements JE. Simian immunodeficiency virus infection in the brain and lung leads to differential type I interferon signaling during acute infection. J Immunol. 2011;186:4008–4018. doi:10.4049/jimmunol.1003757.
   PubMed Web of Science ®Google Scholar
• McNamara LA, Collins KL. Interferon alfa therapy: toward an improved treatment for HIV infection. J Infect Dis. 2013;207:201–203. doi:10.1093/infdis/jis667.
   PubMed Web of Science ®Google Scholar
• Azzoni L, Foulkes AS, Papasavvas E, et al. Pegylated interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis. 2013;207:213–222. doi:10.1093/infdis/jis663.
   PubMed Web of Science ®Google Scholar
• Sun H, Buzon MJ, Shaw A, et al. Hepatitis C therapy with interferon-α and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus coinfected patients. J Infect Dis. 2014;209:1315–1320. doi:10.1093/infdis/jit541.
   PubMed Web of Science ®Google Scholar
• Jiao Y-M, Weng W-J, Gao Q-S, et al. Hepatitis C therapy with interferon-α and ribavirin reduces the CD4 cell count and the total, 2LTR circular and integrated HIV-1 DNA in HIV/HCV co-infected patients. Antiviral Res. 2015;118:118–122. doi:10.1016/j.antiviral.2015.03.011.
   PubMed Web of Science ®Google Scholar
• Morón-López S, Gómez-Mora E, Salgado M, et al. Short-term treatment with interferon alfa diminishes expression of HIV-1 and reduces CD4+ T-cell activation in patients coinfected with HIV and hepatitis C virus and receiving antiretroviral therapy. J Infect Dis. 2016 Mar 15;213:1008–1012. doi:10.1093/infdis/jiv521.
   PubMedGoogle Scholar
• Cachat A, Chevalier SA, Alais S, et al. Alpha interferon restricts human T-lymphotropic virus type 1 and 2 de novo infection through PKR activation. J Virol. 2013;87:13386–13396. doi:10.1128/JVI.02758-13.
   PubMed Web of Science ®Google Scholar
• Cachat A, Alais S, Chevalier S, et al. ADAR1 enhances HTLV-1 and HTLV-2 replication through inhibition of PKR activity. Retrovirology. 2014;11:93. doi:10.1186/s12977-014-0093-9.
   PubMed Web of Science ®Google Scholar
• Abad M, Dronda F, Dominguez E, et al. HTLV-2b among HIV type 1-coinfected injecting drug users in Spain. AIDS Res Hum Retroviruses. 2011;27:579–583.
   PubMed Web of Science ®Google Scholar
• Treviño A, Aguilera A, Caballero E, et al. Trends in the prevalence and distribution of HTLV-1 and HTLV-2 infections in Spain. Virol J. 2012;9:71. doi:10.1186/1743-422X-9-71.
   PubMed Web of Science ®Google Scholar
• Pilotti E, Bianchi MV, De Maria A, et al. HTLV-1/-2 and HIV-1 coinfections: retroviral interference on host immune status. Front Microbiol. 2013;4:372. doi:10.3389/fmicb.2013.00077.
   PubMed Web of Science ®Google Scholar
• Abad-Fernandez M, Dronda F, Moreno A, et al. Brief report: reduced cell-associated HTLV-2 DNA in antiretroviral treated HIV-1-HCV-coinfected patients who either received interferon-alpha/ribavirin-based hepatitis C therapy or had spontaneous HCV RNA clearance. J Acquir Immune Defic Syndr. 2015;69:286–290. doi:10.1097/QAI.0000000000000608.
   PubMed Web of Science ®Google Scholar
• Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas and Bennetts’s principles and practice of infectious diseases. Chap. 47. 8th ed. Philadelphia (PA): Elsevier; 2015. p. 578.
   Google Scholar
• Andersohn F, Claes AK, Kulp W, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison. BMC Infect Dis. 2016;16:10. doi:10.1186/s12879-015-1311-3.
   PubMed Web of Science ®Google Scholar
• Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839–2848. doi:10.1001/jama.292.23.2839.
   PubMed Web of Science ®Google Scholar
• Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004;18:27–36. doi:10.1097/00002030-200409030-00003.
   Web of Science ®Google Scholar
• Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451–459. doi:10.1056/NEJMoa032653.
   PubMed Web of Science ®Google Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438–450. doi:10.1056/NEJMoa040842.
   PubMed Web of Science ®Google Scholar
• Gara N, Ghany MG. What the infectious disease physician needs to know about pegylated interferon and ribavirin. Clin Infect Dis. 2013;56:1629–1636. doi:10.1093/cid/cit074.
   PubMed Web of Science ®Google Scholar
• Kowdley KV. Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol. 2005;39:3–8. doi:10.1097/01.mcg.0000145494.76305.11.
   PubMed Web of Science ®Google Scholar
• Rivero-Juarez A, Gonzalez R, Frias M, et al. KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy. Pharmacol J. [In press] 2016. doi:10.1038/tpj.2016.19.
   Google Scholar
• Deeks SG. HIV: shock and kill. Nature. 2012;487:430–440. doi:10.1038/487439a.
   Google Scholar
• Olesen R, Vigano S, Rasmussen TA, et al. Innate immune activity correlates with CD4 T cell-associated HIV-1 DNA decline during latency-reversing treatment with panobinostat. J Virol. 2015;89:10176–10189. doi:10.1128/JVI.01484-15.
   PubMed Web of Science ®Google Scholar
• Eron SJ, Gay C, Bosch R, et al. Immunologic and virologic activity of anti-PD-L1 in HIV-1 participants on ART. Conference on Retroviruses and Opportunistic Infections; 2016 Feb 22–25; Boston (MA). Abstract O-25
   Google Scholar
• Whitney JB, Lim SY, Osuna CE, et al. Repeated TLR7 agonist treatment of SIV+ monkeys on ART can lead to viral remission. Conference on Retroviruses and Opportunistic Infections; 2016 Feb 22–25; Boston (MA). Abstract 95LB
   Google Scholar